Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach §130a Abs. 8 SGB V zum Wirkstoff Dexamethason (ausschließlich Darreichungsform IMP), ATC S01BA01 für die Zeit 01.04.2026 - 31.03.2028

Section 130a Paragraph 8 of the SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines reimbursed by the statutory health insurance. With regard to the relevant legal provisions for the awarding of public contracts, the DAK-Gesundheit regularly conducts active substance-related, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, relating to the above-mentioned active substance Dexamethasone (IMP dosage form only), ATC S01BA01, the DAK-Gesundheit intends to conclude medicine discount contracts with as many interested pharmaceutical companies as possible until new medicine discount contracts come into force. A discount contract under the approval model for the above-mentioned active substance will come into force for the first time on 01.04.2026 and will end on 31.03.2028. It will end automatically with the entry into force of the exclusive contract, regardless.